Drugs / CD19-targetd CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06569472 | Jul 2024 → Jul 2027 expected | juvenile dermatomyositis | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-targetd CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06569472 ↗ |
| Action | Deplete | “CD19 CAR-T can also cause deep depletion of other CD19+ B cells while killing cancer cells” NCT06569472 ↗ |
| Modality | Cell therapy | “CD19-targetd CAR-T” NCT06569472 ↗ |
| Route | Intravenous | “received a single intravenous cell infusion” NCT06569472 ↗ |